Bile News and Research

RSS

Soy protein lowers total cholesterol and non-HDL: New study

Soy protein's ability to lower total and LDL cholesterol has been extensively studied, but the mechanism whereby soy protein lowers cholesterol remains unresolved. A new study published in the Journal of Clinical Lipidology last month shows that soy protein lowers total cholesterol and non-HDL cholesterol significantly more than milk protein in patients with moderately high cholesterol levels.

18 Jan 2011

Health Canada approves GORE VIABIL Biliary Endoprosthesis device

W. L. Gore & Associates, Inc. today announced it has received approval from Health Canada for the Removable GORE VIABIL Biliary Endoprosthesis.

17 Jan 2011

Carrots and plums for better looks!

Researchers at St Andrews and Bristol universities have found that carrots and plums could make one more attractive in just two months. They found that these fruits and vegetables contain pigments called carotenoids that color the skin within two months making a person more attractive and healthy.

9 Jan 2011

Critical tuning dial for controlling whole body energy

Researchers have found what appears to be a critical tuning dial for controlling whole body energy, according to a new report in the January issue of Cell Metabolism, a Cell Press publication. When energy levels within cells drop, it sets off a series of events designed to increase the amount of calorie-rich dietary fat that the body will absorb.

5 Jan 2011

Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation

Researchers from Italy determined that radiofrequency ablation (RFA) is a safe and effective therapy for managing hepatocellular carcinoma (HCC) in cirrhotic patients. The high repeatability of RFA is advantageous in controlling recurrences of cancerous tumors in the liver. Results of this 10-year retrospective study are available in the January 2011 issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

16 Dec 2010

RFA highly valuable therapy for controlling cancerous nodules

16 Dec 2010

EFSA publishes positive opinion on disease risk reduction health claim for oat beta-glucan

A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.

9 Dec 2010

Interventional Radiology physician utilizes SUPERA VERITAS system to treat biliary stricture

IDEV Technologies, Incorporated, an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced the first procedure in the United States utilizing the SUPERA VERITAS Transhepatic Biliary System, which was recently cleared to market by the U.S. Food and Drug Administration.

30 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

Anti-enolase antibody may contribute to bile duct injury in biliary atresia: Research

Researchers at the University of Colorado School of Medicine and The Children's Hospital have taken a big step toward understanding what causes one of the most serious liver diseases in infants.

27 Oct 2010

New report highlights numerous monoclonal antibodies for treating digestive system cancers

Since the early development of monoclonal antibodies (mAbs), almost forty years ago, twenty-four therapeutic mAbs have been approved, four of them targeting digestive system cancers. Due to this success (two blockbusters reaching sales of over $1 billion), many industrials position themselves on this very attractive sector.

25 Oct 2010

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

Study: Stricture recurrence rate is low, recurrence can be retreated endoscopically

Researchers from Italy have reported results from more than 10 years of follow-up showing that the placement of multiple endoscopic stents for the treatment of postoperative biliary strictures remains excellent with a low rate of stricture recurrence after this lengthy period of time. When strictures do recur, they can be safely and successfully retreated endoscopically. The study appears in the September issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).

22 Sep 2010

Blood test developed for non-alcoholic fatty liver disease diagnosis

Scientists at the Basque Center for Cooperative Research in Biosciences (CIC bioGUNE) and OWL Genomics Ltd. (Bilbao, Spain), in collaboration with researchers at the INSERM and University Hospitals (APHP Pitié Salpêtrière Hospital, Pierre & Marie Curie University Paris and Centre Hospitalier Universitaire Nice, University of Nice-Sophia-Antipolis, Nice, France), Vanderbilt University (Nashville, US), the University of Southern California (Los Angeles, US), Clinic Hospital and IDIBAPS (Barcelona, Spain) and the Alcalá de Henares University (Alcalá de Henares, Spain) have used metabolomics technology to develop a blood test for non-alcoholic fatty liver disease (NAFLD) diagnosis.

19 Sep 2010

Researchers identify role of bile acid in lifespan extension

The human quest for longer life may be one step closer, thanks to research from Concordia University. Published in the journal Aging, a new study is the first to identify the role of a bile acid, called lithocholic acid (LCA), in extending the lifespan of normally aging yeast. The findings may have significant implications for human longevity and health, as yeast share some common elements with people.

16 Sep 2010

ABCB4 gene causes bad cholesterol to accumulate in blood: Research

Scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio have found a gene that causes high levels of bad cholesterol to accumulate in the blood as a result of a high-cholesterol diet.

16 Sep 2010

Scientists discover synergistic effect to delay fat digestion

Institute of Food Research scientists have discovered an unexpected synergy that helps break down fat. The discovery provides a focus to find ways to slow down fat digestion, and ultimately to create food structures that induce satiety.

19 Aug 2010

Merlin protein controls adult cell activity to cause liver cancer

A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer. In the August 15 issue of Genes & Development, a Massachusetts General Hospital (MGH) research team describes finding that the protein called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls the activity of adult stem cells that give rise to the two major types of liver cells.

13 Aug 2010